726.78MMarket Cap-2363P/E (TTM)
3.350High3.180Low517.60KVolume3.250Open3.250Pre Close1.68MTurnover0.42%Turnover RatioLossP/E (Static)224.31MShares9.56052wk High1.76P/B400.26MFloat Cap2.21552wk Low--Dividend TTM123.54MShs Float151.800Historical High--Div YieldTTM5.23%Amplitude2.215Historical Low3.248Avg Price1Lot Size
CureVac Stock Forum
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study
in Patients with Resected Glioblastoma
·First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
·Part B expected to include up to 20 patients to generate extended data on safety, tolerabil...
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
No comment yet